In-capromab pendetide single photon emission computed tomography (SPECT)/CT were performed within 6 weeks of each other. Studies were evaluated by two experienced interpreters for abnormal uptake suspicious for recurrent disease in the prostate bed and extraprostatic locations. The reference standard was a combination of tissue correlation , imaging, laboratory, and clinical data. Diagnostic performance measures were calculated and tests of the statistical signifi cance of differences determined by using the McNemar x 2 test as well as approximate tests based on the difference between two proportions.
Results:
For disease detection in the prostate bed, anti -3- 18 F-FACBC had a sensitivity of 89 % (32 of 36 patients; 95% confi dence interval [CI] : 74%, 97%), specifi city of 67% (eight of 12 patients; 95% CI: 35%, 90%), and accuracy of 83% (40 of 48 patients; 95% CI: 70%, 93%). 111 In-capromab pendetide had a sensitivity of 69% (25 of 36 patients; 95% CI: 52%, 84%), specifi city of 58% (seven of 12 patients; 95% CI: 28%, 85%), and accuracy of 67% (32 of 48 patients; 95% CI: 52%, 80%). In the detection of extraprostatic recurrence, anti -3- 18 F-FACBC had a sensitivity of 100% (10 of 10 patients; 95% CI: 69%, 100%), specifi city of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 100% (17 of 17 patients; 95% CI: 80%, 100%). 111 In-capromab pendetide had a sensitivity of 10% (one of 10 patients; 95% CI: 0%, 45%), specifi city of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 47% (eight of 17 patients; 95% CI: 23%, 72%).
Conclusion:
anti -3-18 F-FACBC PET/CT was more sensitive than 111 Incapromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma and is highly accurate in the differentiation of prostatic from extraprostatic disease. 
Materials and Methods
One author (M.M.G.) and Emory University are eligible to receive royalties from the radiotracer being studied. The other authors had control of the data that might be a confl ict for the author with a potential confl ict of interest.
Preparation of anti -3-18 F-FACBC
The preparation of anti -3-
18
F-FACBC has been previously reported ( 20 ) . The decay-corrected radiochemical yield of the desired product was 24%, and its radiochemical purity was 99% 80 minutes after the end of bombardment. The mass of amino acids, predominantly anti -1-amino-3-hydroxycyclobutane-1-carboxylic acid, in the production batch was approximately 1.5 mg or 9.0 m mol, and the specifi c activity was 580-820 P rostate carcinoma is the second leading cause of death in men in the United States, with 32 050 estimated deaths in 2010 ( 1 ) . The presence of an elevated prostate-specifi c antigen (PSA) level after defi nitive therapy for prostate cancer is suggestive of recurrence. Although approximately 30% of patients will experience recurrence of elevated PSA levels, those with biochemical failure may not manifest clinical disease (2) (3) (4) .
Recurrence can occur within the prostate bed, in extraprostatic locations, or both. The restaging of patients with stage D0 disease (biochemical recurrence after defi nitive therapy) is crucial because the differentiation of prostatic bed from extraprostatic recurrence is vital for tailoring subsequent therapy, especially the use of salvage techniques. This differentiation cannot be made with PSA values alone, although a faster PSA doubling time may be indicative of a higher risk for distant disease ( 5,6 ).
Typically, restaging is performed with a combination of ultrasonography (US)-guided transrectal biopsy, bone scanning, computed tomography (CT), and magnetic resonance (MR) imaging (7) (8) (9) (10) (11) In-capromab pendetide scans. Uptake was considered to be abnormal when there was activity or asymmetries of increased uptake compared to background expected biodistribution in normal adjacent organs or structures (22) (23) (24) .
Reference Standard
The prostate bed in patients with either positive or negative imaging studies was typically investigated with transrectal US and biopsy as clinically appropriate. For patients who had previously undergone prostatectomy, biopsy was not performed if negative imaging studies were obtained at the surgical site and transrectal US did not show abnormal tissue in which to target.
Patients with abnormal foci in extraprostatic tissue at imaging were further investigated by using a combination of percutaneous imaging-guided needle biopsy, laparoscopic techniques, and open lymph node dissection. Because it is unusual for prostate carcinoma to metastasize to inguinal nodes, it was agreed that the inguinal regions would be evaluated with physical examination and percutaneous biopsy performed only if fi ndings were suspicious for carcinoma.
A ground truth panel composed of a nuclear radiologist (D.M.S.), two urologists (P.T.N. and V.A.M., with 32 and 8 years of experience, respectively), and a radiation oncologist (P.J.R., with 5 years of experience) met at a regular conference and communicated via e-mail. Truth was ascertained by means of the criteria outlined below. If there were initial differences of opinion, further discussion ensued until a consensus was achieved.
The presence of disease in the prostate bed was confi rmed by means of biopsy, with truth overridden only with use of clinical data . For example, a substantial reduction in PSA level after prostatic bed salvage ther apy without intravenous contrast material at 2.5 mA and 140 kVp (VG/Hawkeye) or 120 mA and 130 kVp (Symbia T6). SPECT was performed with a 128 3 128 matrix with no zoom and with either 120 60-second projections (VG/Hawkeye) or 60 100-second projections (Symbia T6); images were reconstructed with and without attenuation correction by using iterative reconstruction with appropriate postreconstruction fi ltering. Images were then viewed on a workstation (Xeleris, GE Medical Systems). One patient underwent
111
In-capromab pendetide SPECT at another facility, and his images were fused with separately acquired CT scans by using software .
Image Analysis
One nuclear radiologist with 14 years of experience (D.M.S.) and one nuclear medicine physician with 25 years of experience (R.K.H.) assessed both the anti -3-18 F-FACBC and 111 In-capromab pendetide studies. The investigators had access to the patient's history but not to the results of recent imaging studies. The anti -3-18 F-FACBC scans were interpreted individually by each reader, with disagreements to be resolved by consensus; however, there were no discrepancies. 111 In-capromab pendetide scans were interpreted in a separate combined session by both readers; this reading session was performed at least 2 weeks later to minimize recall bias.
For anti -3-
18
F-FACBC scans, uptake in the focus was compared with that in background structures and classifi ed as mild (higher than that of blood pool but less than that of marrow), moderate (higher than or equal to that of marrow but less than that of liver), or intense (equal to or higher than that of liver). Quantitative criteria (maximum standardized uptake value in the lesion/mean standardized uptake value in background) were used to aid the visual analysis. The maximum and mean standardized uptake values were recorded for each focus of abnormal uptake as well as for background structures including liver, marrow at L3, aorta, and bladder. An edge-seeking conformational volume of interest tool (PET Edge, MIMvista) was typically used. For prostate beds as greater after prostatectomy ; (c) bone scans were negative for metastatic disease; and (d) 111 In-capromab pendetide and anti -3-18 F-FACBC studies were performed within 6 weeks of each other.
anti -3-
F-FACBC Imaging Protocol
Scanning was conducted by using a positron emission tomography (PET)/CT unit (Discovery DLS; GE Medical Systems, Milwaukee, Wis), and scans were interpreted on a workstation with use of software (MIMvista 4.2; MIMvista, Cleveland, Ohio). All patients fasted for 4-6 hours before undergoing scanning with anti -3-18 F-FACBC. After patients underwent CT of the abdomen and pelvis (80-120 mA, 120 kVp) with oral contrast material and without intravenous contrast material, anti -3-18 F-FACBC (199.8-484.7 MBq) was injected intravenously over 2 minutes. After a 3-minute delay for blood pool clearance, PET was performed with three contiguous acquisitions (4 minutes per frame) starting from the pelvis below the prostate and extending superiorly to include the abdomen above the kidneys. This process was repeated twice. Thus, 5-16-minute (early), 17-28-minute (delayed 1), and 29-40-minute (delayed 2) acquisitions were performed. Images above the diaphragm were not acquired. In-capromab pendetide. Patients underwent imaging without fasting by using a protocol similar to that used by Soddee and co-workers ( 21 In-capromab pendetide, with sensitivities of 100% (10 of 10 patients; 95% CI: 69%, 100%) and 10% (one of 10 patients; 95% CI: 0%, 45%), respectively ( P = .003). Figure 3 and Table 3 summarize data and reference standards applied for extraprostatic disease. Table 2 includes a summary of diagnostic performances.
Extraprostatic recurrence was limited to lymph nodes in eight patients and to bone in one patient. One patient had both nodal and bone involvement. Figure 4 illustrates the detection of extraprostatic disease in a 5-mm node with anti -3- 
Discussion
We set out to determine the diagnostic performance of anti -3- In-capromab pendetide SPECT/CT.
Our fi ndings are important because approximately one-third of patients will have biochemical evidence of recurrence and the therapeutic approach a subsequent substantial increase in PSA level in 6 months would establish not only the presence of presumed prostatic bed disease but also the absence of extraprostatic disease. Extraprostatic nodal involvement per patient was confi rmed by means of patho logic proof alone. Skeletal involvement was confi rmed with either biopsy or a typical appearance on MR images ( 25 ) . The absence of extraprostatic disease was confi rmed with either a substantial reduction in PSA level after prostatic bed therapy without a substantial increase in 6 months as mentioned earlier and/or stable appearance on CT or MR images for more than 1 year without evidence of nodal or bone involvement. Because some patients had defi nitive follow-up results for prostate bed but not extraprostatic disease, and vice versa, the number of patients in each subanalysis differed.
Statistical Analyses
The statistical analyses provided measures of diagnostic performance (eg, sensitivity, specifi city, negative predictive value, and positive predictive value) along with the associated confi dence intervals (CIs). We determined the statistical signifi cance of differences in sensitivity, specifi city, and overall accuracy between anti -3-18 F-FACBC and 111 In-capromab pendetide by using the McNemar x 2 test to adjust for correlations in the accuracy measures. The signifi cance of differences for other diagnostic performance measures (positive and negative predictive values) was assessed by using approximate tests based on the difference between two proportions. Statistical significance was determined by using a type I error rate of a = 0.05 for overall comparisons. Statistical analyses were performed by using MatLab software (version 7.10; MathWorks, Natick, Mass) and the R statistical package (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org ).
Results

Demographics
Fifty patients met the inclusion criteria. The mean patient age ( 6 standard deviation) was 68.3 years 6 8.1 (range, 50-90 years), and the mean PSA level was 6.62 ng/mL 6 7.63 (range, 0.11-44.74 ng/mL). PSA values were obtained within 16.8 days 6 37.4 of anti -3-18 F-FACBC scanning. 111 In-capromab pendetide studies were performed within 15.7 days 6 10.9 (range, 2-37 days) of anti -3-18 F-FACBC scanning. Thirteen patients originally underwent radical prostatectomy, and 37 patients were treated with cryotherapy, high-frequency ultrasound, external beam ra diation therapy, and/or brachytherapy. Forty-eight patients had defi nitive follow-up results for the prostate bed and 17 had defi nitive follow-up results for extraprostatic disease. In-capromab pendetide, with sensitivities of 89% (32 of 36 patients; 95% CI: 74%, 97%) and 69% (25 of 36 patients; 95% CI: 52%, 84%), respectively ( P = .035). Figure 1 and Table 1 summarize data and reference standards applied for the prostatic bed. Table 2 includes a summary of diagnostic performances.
Four patients had false-positive fi ndings in the prostate bed with anti -3-18 F-FACBC; these patients also had false-positive fi ndings with 111 In-capromab pendetide. Three of these four patients originally underwent a nonradical prostatectomy treatment, and one patient underwent radical prostatectomy. Infl ammation was not present in any biopsy sample. Benign glands and stroma were reported in two of the four patients, treatment-related changes were reported in one patient, and benign gland and stroma with fi bromuscular tissue and a single lymphoid aggregate were reported in one patient. Four patients had false-negative fi ndings with anti -3-18 F-FACBC; three of these patients also had false-negative fi ndings with 111 In-capromab pendetide. Two of the four patients had undergone radical prostatectomy and two had undergone a nonradical prostatectomy
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Schuster et al membrane antigen ( 26 ) . Its sensitivity and specifi city in the detection of recurrent prostate carcinoma was originally reported to be 62% and 72%, respectively ( 9 ). Yet, diagnostic performance in the subsequent literature varied widely, with sensitivities of 17%-92% and specifi cities of 47%-86%-likely refl ecting differences in intraobserver variability and study population and design ( 9,11-14, 27,28 ). Fusion with CT or MR images has been reported to improve accuracy ( 24, 26, 29 ) . In our study, the sensitivity of 111
In-capromab pendetide was 69% for detecting disease in the prostate bed and 10% for detecting disease in extraprostatic sites.
Seltzer and co-workers ( 13 ) also compared 111 In-capromab pendetide im ages to biopsy-sampled nodes and reported that fi ndings from In-capromab pendetide helps detect the intracellular epitope of prostate-specific membrane antigen, which is problematic when the radiotracer is not internalized ( 23 ) . In addition, the use of anti -3-18 F-FACBC with PET results in images with higher spatial resolution than those obtained with SPECT, possibly contributing to the differences in detection between the two radiotracers in our study. Newly reported advanced SPECT reconstruction methods with 111 In-capromab pendetide may improve accuracy ( 30, 31 ) .
CT is considered of low yield in the detection of recurrent local disease, with one study ( 32 ) reporting positive results in only 36% of cases, refl ecting the diffi culty in distinguishing recurrence from scar. Dynamic contrast materialenhanced MR imaging is used more frequently for the detection of local recurrence, with sensitivities of 70%-95% and specifi cities of 73%-100% depending on the type of previous therapy (33) (34) (35) (36) . Routine MR imaging and CT are limited in the detection of nodal involvement, with typical sensitivities in the lower range of 25%-78% and specifi cities of 66%-100% ( 26,37-41 ). MR imaging with superparamagnetic particles may depends not only on confi rming recurrence but, most important, determining whether recurrence is confi ned to the prostate bed or located at extraprostatic sites ( 2 ) . The suspected location of distant disease may be evaluated with a combination of bone scanning, CT, and MR imaging. Each of these techniques has its limitations ( 9-11 ). A noninvasive method for guiding pathologic confi rmation on a whole-body basis is important ( 14 ).
111
In-capromab pendetide is a radiolabeled murine monoclonal antibody that binds to prostate-specific
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Schuster et al be more promising for lymph node assessment, with a reported per-patient sensitivity of 80%-100% and specifi city of 73%-95.7% (40) (41) (42) . FDG PET has little utility for normally slow-growing prostate carcinoma, with detection rates in the range of 31%-66% ( 43, 44 ) ; better diagnostic performance was obtained for more aggressive disease ( 43 ) . Interpretation of FDG PET scans of the pelvis is also hampered by renal excretion of FDG. PET/CT and iterative reconstruction techniques may result in improved accuracy.
Other PET and SPECT radiotracers are undergoing investigation ( 39, (45) (46) (47) (48) . The most well studied of these radiotracers are carbon 11 ( 11 C)-choline and 18 F-choline, with published sensitivities of 36%-100% and specifi cities of 12.5%-100% ( 33, (48) (49) (50) .
11
C-acetate has also been investigated, with sensitivities reported to be 75%-83% ( 48 ) .
11 Cmethionine is an amino acid radiotracer that, in limited studies, demonstrated a sensitivity of 72% in the detection of metastatic prostate cancer ( 44 ) and an overall detection rate of 46.7% for primary carcinoma ( 51 ) .
In this study, anti -3-18 F-FACBC PET/CT demonstrated 89% sensitivity and 67% specifi city in the detection of local recurrence in the prostate bed and 100% sensitivity and specifi city in the detection of extraprostatic disease; these findings compare favorably to those with the above-mentioned techniques. Comparison on the basis of published studies alone, however, is problematic owing to differences in patient populations, study methodology, and reference standards used to establish truth. For example, diagnostic performance may be dependent on PSA level and scan method (eg, PET alone vs PET/CT).
We chose to make this comparison to conventional imaging with 111 Incapromab pendetide because that is the current standard of care in our institution
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Schuster et al In-capromab pendetide and anti -3-18 F-FACBC. Table 3 Reference choline PET/CT and/or advanced MR imaging, ideally with use of the patient as his or her own control in a multicenter environment, should be carried out before clinical recommendations can be made.
One limitation of a clinical study involving prostate carcinoma is the dilemma in establishing truth for absence of disease. PSA level in isolation is not an adequate end point and must be correlated in clinical context. Even an increase in PSA level after prostatectomy does not necessarily equate with clinical failure ( 2, 4 ) . Yet, prostate biopsies-especially those performed after therapy-are subject to sampling error and may underestimate true-positive disease ( 7, 8, 33, 52, 53 ) . Most of our patients underwent nonradical prostatectomy procedures in which an increase in PSA level may be due to prostatitis or benign hypertrophy. A patient is more likely to receive salvage radiation therapy after radical prostatectomy with increasing PSA level and negative biopsy than after a nonradical prostatectomy technique in which biopsy proof is usually required at lower PSA levels before undergoing salvage surgery or cryotherapy.
There is no ideal method with which to establish truth in all circumstances, as refl ected in the acceptable practice variations in the restaging of patients with prostate carcinoma ( 2 ) . We chose to default to biopsy fi ndings, which were overridden only with data obtained during the patient's subsequent clinical and therapeutic course . If there was insuffi cient proof of the presence or absence of disease, the outcome was then considered indeterminate awaiting further follow-up. Thus, each patient was independently Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received money for patent (planned, pending, or issued) from Nihon Medi-Physics; institution received money for patent (planned, pending, or issued) from Nihon Medi-Physics; received royalties from Nihon Medi-Physics; institution received royalties from Nihon Medi-Physics. Other relationships: none to disclose.
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